{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Muth ST"],"funding":["Bristol-Myers Squibb","National Cancer Institute","NCI NIH HHS"],"pagination":["99-108"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7779747"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["499"],"pubmed_abstract":["Pancreatic ductal adenocarcinoma(PDAC) is resistant to the PD-1/PD-L1 blockade therapy. Previously, the combination of PD-1 blockade and vaccine therapy was shown to have a modest antitumor activity in murine models of PDAC. We used a murine syngeneic model of metastatic PDAC to identify, among multiple T cell modulators tested, which therapeutic agents in combination with the GVAX cancer vaccine and an anti-PD-1 antagonist antibody(αPD-1) are able to improve the survival. We found that an anti-CD137 agonist antibody(αCD137) most significantly improved survival in the mouse PDAC model. Moreover, αPD-1 and αCD137 together in combination with vaccine therapy more significantly increased the expression of costimulatory molecules CD137 and OX40 on CD4+PD-1+ and CD8+PD-1+ T cells comparing to α"],"journal":["Cancer letters"],"pubmed_title":["CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma."],"pmcid":["PMC7779747"],"funding_grant_id":["P30 CA006973","T32 CA009071","R01 CA197296","T32 CA126607","R01 CA169702","K23 CA148964","P50 CA062924"],"pubmed_authors":["Blair AB","Saung MT","Zheng L","Thomas DL","Muth ST","Henderson MG"],"additional_accession":[]},"is_claimable":false,"name":"CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.","description":"Pancreatic ductal adenocarcinoma(PDAC) is resistant to the PD-1/PD-L1 blockade therapy. Previously, the combination of PD-1 blockade and vaccine therapy was shown to have a modest antitumor activity in murine models of PDAC. We used a murine syngeneic model of metastatic PDAC to identify, among multiple T cell modulators tested, which therapeutic agents in combination with the GVAX cancer vaccine and an anti-PD-1 antagonist antibody(αPD-1) are able to improve the survival. We found that an anti-CD137 agonist antibody(αCD137) most significantly improved survival in the mouse PDAC model. Moreover, αPD-1 and αCD137 together in combination with vaccine therapy more significantly increased the expression of costimulatory molecules CD137 and OX40 on CD4+PD-1+ and CD8+PD-1+ T cells comparing to α","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Feb","modification":"2026-05-09T03:21:23.646Z","creation":"2025-04-04T22:15:37.746Z"},"accession":"S-EPMC7779747","cross_references":{"pubmed":["33271264"],"doi":["10.1016/j.canlet.2020.11.041"]}}